Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
Arlene A. Forastiere,Qiang Zhang,Randal S. Weber,Moshe H. Maor,Helmuth Goepfert,Thomas F. Pajak,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,Wade L. Thorstad,Henry N. Wagner,John F. Ensley,Jay S. Cooper +13 more
TLDR
These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS, and new strategies that improve organ preservation and function with less morbidity are needed.Abstract:
Purpose To report the long-term results of the Intergroup Radiation Therapy Oncology Group 91-11 study evaluating the contribution of chemotherapy added to radiation therapy (RT) for larynx preservation. Patients and Methods Patients with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomitant cisplatin/RT, or RT alone. The composite end point of laryngectomy-free survival (LFS) was the primary end point. Results Five hundred twenty patients were analyzed. Median follow-up for surviving patients is 10.8 years. Both chemotherapy regimens significantly improved LFS compared with RT alone (induction chemotherapy v RT alone: hazard ratio [HR], 0.75; 95% CI, 0.59 to 0.95; P = .02; concomitant chemotherapy v RT alone: HR, 0.78; 95% CI, 0.78 to 0.98; P = .03). Overall survival did not differ significantly, although there was a possibility of worse outcome with concomitant relative to induction chemother...read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Head and neck squamous cell carcinoma
Daniel Johnson,Barbara Burtness,C. René Leemans,Vivian Wai Yan Lui,Julie E. Bauman,Jennifer R. Grandis +5 more
TL;DR: This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
Journal ArticleDOI
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
TL;DR: The changing epidemiology, advances in diagnosis, and treatment options for squamous cell cancers of the head and neck, along with data on risk stratification specific to oropharyngeal cancer are focused on, and the direction of current trials is highlighted.
Journal ArticleDOI
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Hisham Mehanna,Max Robinson,Andrew Hartley,Anthony Kong,Bernadette Foran,T. Fulton-Lieuw,M. Dalby,Pankaj Mistry,Mehmet Sen,L. O'Toole,Al, Booz, H,Karen Dyker,Rafael Moleron,S Whitaker,S. Brennan,Audrey Cook,Matthew E. Griffin,E. Aynsley,M Rolles,De, Winton, E,Andrew K Chan,D. Srinivasan,I Nixon,Joanne Grumett,C.R. Leemans,Jan Buter,J Henderson,Kevin J. Harrington,Christopher C. McConkey,Alastair Gray,Janet A. Dunn +30 more
TL;DR: Cisplatin and radiotherapy should be used as the standard of care for HPV-positive low-risk patients who are able to tolerate cisplatin, and cetuximab showed significant detriment in terms of tumour control.
Journal ArticleDOI
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
David G. Pfister,Sharon A. Spencer,David J. Adelstein,Douglas Adkins,Yoshimi Anzai,David M. Brizel,Justine Yang Bruce,Paul M. Busse,Jimmy J. Caudell,Anthony J. Cmelak,A. Dimitrios Colevas,David W. Eisele,Moon Fenton,Robert L. Foote,Thomas J. Galloway,Maura L. Gillison,Robert I. Haddad,Wesley L. Hicks,Ying J. Hitchcock,Antonio Jimeno,Debra S. Leizman,Ellie Maghami,Loren K. Mell,Bharat B. Mittal,Harlan A. Pinto,John A. Ridge,James W. Rocco,Cristina P. Rodriguez,Jatin P. Shah,Randal S. Weber,Gregory S. Weinstein,Matthew E. Witek,Frank Worden,Sue S. Yom,Weining Zhen,Jennifer L. Burns,Susan Darlow +36 more
TL;DR: The NCCN Guidelines for Head and Neck Cancers as mentioned in this paper describe supportive care recommendations for patients with H&N cancers and the rationale supporting a new section on imaging recommendations for head and neck cancers.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.